• Dawn M Bravata, Nancy Lightner, H Klar Yaggi, and Edward J Miech.
• Veterans Affairs Center for Applied Systems Engineering (VA-CASE), Indianapolis, Indiana. dawn.bravata2@va.gov.
• Respir Care. 2018 Jan 1; 63 (1): 50-61.

BackgroundA dilemma faced by health-care administrators is that need greatly outstrips capacity for diagnosing and treating sleep apnea, with such decisions carrying significant economic consequences. Our objective was to develop an economic model to estimate the relative costs of 4 approaches for diagnosis and initial treatment of sleep apnea.MethodsThe analysis consisted of developing a mathematical model depicting possible diagnostic and treatment approaches to the care of patients with sleep apnea; developing 4 clinical scenarios to describe distinct approaches to the management of sleep apnea patients (in-laboratory, unattended, direct-to-autotitrating PAP [auto-PAP], and mixed); and identifying costs associated with each scenario. We created a hypothetical cohort of 1,000 patients with 85% prevalence of sleep apnea to generate cost estimates.ResultsThe driver of per-patient costs was the total number of sleep studies, which varied widely across scenarios: from 425 for the direct-to-auto-PAP approach to 1,441 in the unattended approach. The scenarios also differed in per-patient costs: Per-patient costs excluding facility startup costs were $456 for direct-to-auto-PAP, $913 for in-laboratory, $991 for mixed, and $1,090 for unattended.ConclusionsApproaches to diagnosing and treating sleep apnea that emphasized early application of auto-PAP had lower per-patient costs.Copyright © 2018 by Daedalus Enterprises.

18 keywords...

hide…